Patents by Inventor Daniel Rader

Daniel Rader has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
    Patent number: 11883470
    Abstract: A synthetic or recombinant human lecithin cholesterol acyltransferase (LCAT) variant is provided which comprises an LCAT enzyme having a substitution at position 114 based on the residue numbering of wild-type (WT) human LCAT [SEQ ID NO:1], wherein said variant is characterized by one or more of: (i) an esterification rate higher than the esterification rate of WT human LCAT; and/or (ii) an association with higher density lipoprotein levels as compared to subjects having WT LCAT. Also provided are vectors encoding the variant, compositions containing same, and methods of using the variant proteins and vectors for treatment of a variety of disorders associated with defective wt LCAT.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: January 30, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Daniel Rader, Devin Christopher, Anna P. Tretiakova
  • COMPOSITIONS COMPRISING A LECITHIN CHOLESTEROL ACYLTRANSFERASE VARIANT AND USES THEREOF
    Publication number: 20190282670
    Abstract: A synthetic or recombinant human lecithin cholesterol acyltransferase (LCAT) variant is provided which comprises an LCAT enzyme having a substitution at position 114 based on the residue numbering of wild-type (WT) human LCAT [SEQ ID NO:1], wherein said variant is characterized by one or more of: (i) an esterification rate higher than the esterification rate of WT human LCAT; and/or (ii) an association with higher density lipoprotein levels as compared to subjects having WT LCAT. Also provided are vectors encoding the variant, compositions containing same, and methods of using the variant proteins and vectors for treatment of a variety of disorders associated with defective wt LCAT.
    Type: Application
    Filed: July 24, 2017
    Publication date: September 19, 2019
    Inventors: Daniel Rader, Devin Christopher, Anna P. Tretiakova
  • Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein Al, very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
    Publication number: 20060088504
    Abstract: Compositions and methods for raising the level of HDL cholesterol and apolipoprotein AI in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in a patient, including compositions and methods which effect the expression of a gene, LIPG, which encodes a lipase enzyme that is a member of the triacylglycerol lipase family or which effect the enzymatic activity of the enzyme.
    Type: Application
    Filed: October 19, 2005
    Publication date: April 27, 2006
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Michael Jaye, Kim-Anh Doan, John Krawiec, Kevin Lynch, Dilip Amin, Victoria South, Dawn Marchadier, Cyrille Maugeais, Daniel Rader
  • Resistin as a marker and therapeutic target for cardiovascular disease
    Publication number: 20050244892
    Abstract: The risk or progression of cardiovascular disease and coronary artery disease is assessed in a mammalian subject by measuring the level or concentration of circulating serum resistin in a subject and comparing the measured level to resistin levels within a standardized or standard population. Methods of treating cardiovascular diseases and/or inflammatory disorders involve administering to a patient a composition that can reduce the circulating levels of resistin.
    Type: Application
    Filed: February 28, 2005
    Publication date: November 3, 2005
    Inventors: Mitchell Lazar, Daniel Rader, Muredach Reilly